Biodesix, Inc.
BDSXBiodesix is a leading diagnostic solutions company focused on personalized medicine for lung disease through multi-omic blood-based testing.
Earnings
Next report
Aug 5, 2026 (In 1 week)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
Biodesix is a leading diagnostic solutions company focused on personalized medicine for lung disease through multi-omic blood-based testing. The company leverages genomics, proteomics, and artificial intelligence to provide rapid, actionable insights for clinical diagnosis, treatment guidance, and disease monitoring. Their value proposition centers on improving patient outcomes and reducing healthcare costs by replacing invasive procedures with timely, non-invasive diagnostic tests.
A leader in lung-focused blood-based diagnostics with a unique multi-omic approach and industry-leading turnaround times for test results.
Questions, answered.
- What is Biodesix, Inc.'s market cap?
- Biodesix, Inc. (BDSX) has a market capitalization of $230.1M and trades on NASDAQ.
- What is Biodesix, Inc.'s revenue and profitability?
- Biodesix, Inc. generated $96.1M in trailing twelve-month revenue with a net loss of $32.0M, representing a net margin of -33.3%, with free cash flow of -$25.8M. These figures are based on the Q1 2026 filing.
- Who are Biodesix, Inc.'s competitors?
- Biodesix, Inc.'s key competitors include Personalis, Inc., NeoGenomics, Inc., Veracyte, Inc., and others. These companies compete in similar markets and product categories.
- Who does Biodesix, Inc. partner with?
- Biodesix, Inc.'s notable partners include Bio-Rad Laboratories, Inc., Memorial Sloan Kettering Cancer Center, Freenome, and others.
- What subsidiaries does Biodesix, Inc. have?
- Biodesix, Inc.'s subsidiaries include Integrated Diagnostics (Indi).
- Where is Biodesix, Inc. headquartered?
- Biodesix, Inc. is headquartered in United States of America and employs approximately 217 people. It has been publicly traded since 2020.
